Screener
CytomX Therapeutics CTMX Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by CytomX Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The source filing: CytomX Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:05 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-337950
| Line item | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|
| Amortization of intangible assets | 73 | 73 |
| Depreciation and amortization | 225 | 659 |
| Accretion of discounts on short-term investments | (2,154) | (851) |
| Stock-based compensation expense | 7,283 | 3,439 |
| Non-cash lease expense | 2,497 | 2,189 |
| Changes in operating assets and liabilities | ||
| Accounts receivable | (35,481) | 1,234 |
| Prepaid expenses and other assets | (3,746) | (1,076) |
Item 1. Condensed Financial Statements (Unaudited)
FAQ
- What is CytomX Therapeutics's stock-based comp?
- CytomX Therapeutics (CTMX) reported stock-based comp of $2.58M in Q2 2026.
- How has CytomX Therapeutics's stock-based comp changed year-over-year?
- CytomX Therapeutics's stock-based comp increased by 80.1% year-over-year, from $1.43M to $2.58M.
- What is the long-term trend for CytomX Therapeutics's stock-based comp?
- Over 4 years (2021 to 2025), CytomX Therapeutics's stock-based comp has grown at a -16.8% compound annual growth rate (CAGR), from $13.17M to $6.3M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.
Ask your AI about CytomX Therapeutics's stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude